RxDoctor Payments Data

Neel Khanna, MD

Interventional Cardiology · Newburgh, NYNPI 1124347612

Payments from drug & device makers

$3,757in general payments, 2019–2025

Across 53 payments — averaging $70.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Boston Scientific$558
  • Shockwave Medical, Inc$408
  • Abiomed$357
  • AstraZeneca$355
  • Inari Medical, Inc.$332
  • plus $444 from 5 others

What the payments were for

  • Travel & lodging$68518%
  • Food & beverage$3,07282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,757 in reported general payments places this provider in the 25th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$291,029
Medicare patients
786
Services billed
2,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban150$174,800
Repatha SureclickEvolocumab12$18,693
XareltoRivaroxaban17$18,540
Praluent PenAlirocumab21$14,660
Metoprolol Succinate243$3,472
Atorvastatin Calcium280$2,332
Ranolazine ErRanolazine13$2,043
Valsartan55$1,999
Ezetimibe52$1,757
Nebivolol Hcl20$1,706
Amlodipine Besylate220$1,477
ClopidogrelClopidogrel Bisulfate116$1,063
Rosuvastatin Calcium80$1,009
Losartan Potassium78$993
Lisinopril124$684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$148$18,54017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Newburgh

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →